In order to accelerate development and build a higher level of innovative drug safety evaluation team, Shandong Xinbo Drug Research Co., Ltd. decided to invest in the construction of an innovative drug evaluation platform with the "Shandong Xinbo Drug Research Institute" as the leader in Lishan International Cell Industrial Park.

Xin Chengyao Qi  Lishi Tongxing

On February 1, 2024, Shandong Xinbo Pharmaceutical Research Co., Ltd. and Lishan International Cell Industry Park jointly held a signing ceremony for entry. Company leaders Professor Liu Zhaoping and Ms. Liu Yaling attended the signing ceremony.
At the ceremony, both parties introduced their future development plans to each other, had friendly communication on opening up cooperation channels, promoting resource sharing, and successfully signed the "Minghu International Cell Medicine Industrial Park Industrial Plant Purchase Agreement".

Shandong Xinbo Pharmaceutical Research Institute will focus on conducting safety evaluations of cell-based drugs based on organ chips, toxicology evaluations characterized by drug sensitization research, and drug development platforms with advantages in innovative compound drug efficacy and pharmacokinetics research. Through cooperation with Lishan International Cell Industry Park, we aim to achieve resource sharing, complementary advantages, mutual learning and construction, and mutual benefit, jointly promoting the development of cell therapy products and contributing to the innovation of new drugs in China.